RxDoctor Payments Data

Lindsey Geyer, PA

Physician Assistant · Rochester, NYNPI 1730585043

Payments from drug & device makers

$876in general payments, 2019–2025

Across 19 payments — averaging $46.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$190
  • Daiichi Sankyo Inc.$184
  • Biohaven Pharmaceuticals, Inc.$138
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$119
  • Silk Road Medical, Inc.$65
  • Boehringer Ingelheim$45
  • plus $134 from 5 others

What the payments were for

  • Food & beverage$876100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$876 in reported general payments places this provider in the 70th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$4,670
Medicare patients
53
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban20$26,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$20,346
EliquisApixaban26$18,199
JardianceEmpagliflozin17$14,137
MyrbetriqMirabegron17$7,249
Levothyroxine Sodium145$2,615
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,327
Atorvastatin Calcium138$1,784
Potassium Chloride33$1,215
Lisinopril100$956
Simvastatin50$892
Gabapentin84$885
Rosuvastatin Calcium51$813
Albuterol Sulfate HfaAlbuterol Sulfate29$798
Amlodipine Besylate110$787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$190$20,34631 claims
Boehringer IngelheimJardiance$45$14,13717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →